Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ZK-EPO

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
UNLABELLED Treatments for women with recurrent brain metastases from breast cancer are limited. In this phase II study,we… Expand
2010
2010
BACKGROUND Sagopilone (ZK-EPO) is a fully synthetic microtubule-stabilizing agent that has demonstrated high antitumor activity… Expand
Review
2010
Review
2010
  • E. Rivera
  • American journal of clinical oncology
  • 2010
  • Corpus ID: 22323943
Resistance to chemotherapeutic agents is a significant obstacle to the effective treatment of metastatic breast cancer (MBC… Expand
2009
2009
It has been demonstrated that sagopilone (ZK-EPO) has antitumor activity in human orthotopic glioma models in vitro and in vivo… Expand
  • table 1
  • figure 1
Review
2008
Review
2008
BACKGROUND Tubulin is among the most established and clinically validated targets in oncology. The taxanes, paclitaxel and… Expand
Review
2008
Review
2008
Background: Tubulin is among the most established and clinically validated targets in oncology. The taxanes, paclitaxel and… Expand
Highly Cited
2008
Highly Cited
2008
Sagopilone (ZK-EPO) is the first fully synthetic epothilone undergoing clinical trials for the treatment of human tumors. Here… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2008
2008
5141 Background: The microtubule stabilizer docetaxel, in combination with prednisone, prolongs life in patients with metastatic… Expand
2008
2008
19081 Background: Sagopilone, a novel epothilone, has shown preclinical activity against SCLC cell lines. A completed Phase I… Expand
2008
2008
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand